Defence Therapeutics Inc. (DTC.CN) Research

Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.

Market snapshot

Symbol
DTC.CN
Price
$0.54
Day change
+14.89%
Market cap
$31.0M
P/E ratio
-4.83x
52-week range
0.435-0.93
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • DIAGNOS Inc. (ADK.V)
  • BriaCell Therapeutics Corp. (BCT.TO)
  • The Cannabist Company Holdings Inc. (CBST.NE)
  • Gemina Laboratories Ltd. (GLAB.CN)
  • Microbix Biosystems Inc. (MBX.TO)
  • MedMira Inc. (MIR.V)
  • Resverlogix Corp. (RVX.TO)
  • Sernova Corp. (SVA.TO)

Open Defence Therapeutics Inc. (DTC.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.